Tesamorelin vs IGF-1 DES
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Also: des(1-3)IGF-1, Des(1-3) IGF-I
IGF-1 DES is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. That small cut makes it bind poorly to the IGF binding proteins that normally keep IGF-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. It occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. There are no human trials of it at all, so everything said about it in people is extrapolation.
Key Comparison Insights
- Tesamorelin is FDA approved, while IGF-1 DES remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to IGF-1 DES (Preclinical).
Detailed Comparison
| Attribute | Tesamorelin | IGF-1 DES |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies. | Like regular IGF-1, des(1-3)IGF-1 activates the type 1 IGF receptor, a tyrosine kinase receptor closely related to the insulin receptor. That switches on PI3K/Akt and MAPK signalling, which drives cell growth, protein synthesis and glucose uptake. The difference is the binding proteins. In the body almost all IGF-1 rides around bound to IGFBPs, which limit how much can hit the receptor. Removing the N-terminal tripeptide (Gly-Pro-Glu) sharply weakens IGFBP binding while leaving receptor binding intact. In a 1992 JCI study on rat granulosa cells, des(1-3)IGF-1 was about 10 times more potent than intact IGF-1 when binding proteins were present, and roughly equal once they were removed, which shows the extra potency comes from dodging the binding proteins rather than a stronger receptor hit. The trade-off: unbound IGF-1 is cleared fast, so its action is short and local, which is why people inject it into a specific muscle. It also carries IGF-1's insulin-like effect on blood sugar. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | Community-reported 20-100 mcg per day Usually once daily on training days |
| Administration | Subcutaneous injection | Intramuscular or subcutaneous injection (community practice); studied by injection in animals only |
| Typical Duration | Indefinite for approved indication | Community reports describe short cycles of about 4-6 weeks; there is no human data on safe duration |
| Best Time to Take | Before bed (fasted) | Around training, per community practice |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use. | The research is old, small, and entirely in cells and animals. Sara, Carlsson-Skwirut and colleagues isolated a truncated variant of IGF-1 from human fetal brain in 1986 (PNAS). In GH-deficient lit/lit mice, Gillespie and colleagues (J Endocrinol, 1990) found that 3 microgram daily injections of des(1-3)IGF-1 increased body length about as much as 30 micrograms of regular IGF-1, confirming its higher potency in a living animal; organ weights (kidney, heart) also rose. Adashi and colleagues (JCI, 1992) showed the roughly 10-fold potency gain disappears when IGF binding proteins are removed. Beyond that, it is mostly a lab tool for studying the IGF system. There are no human trials, no pharmacokinetic data in people, and no safety data. Claims about local muscle hyperplasia, fat loss, or recovery are bodybuilding lore built on IGF-1 biology, not on studies of this peptide. Theoretical risks are the same as for IGF-1 and other analogues: low blood sugar, and long-term concerns about feeding the growth of existing tumours, since IGF-1 signalling is a known growth pathway in several cancers. Quality is another unknown: the material sold online has no pharmaceutical oversight. |
Frequently Asked Questions: Tesamorelin vs IGF-1 DES
What is the difference between Tesamorelin and IGF-1 DES?
Tesamorelin is a growth hormone peptide that tesamorelin is a stabilized analog of growth-hormone-releasing hormone (ghrh 1-44) with a chemical modification that protects it from rapid breakdown. it is fda-approved (brand name egrifta) to reduce excess visceral abdominal fat in people with hiv-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online. IGF-1 DES is a growth hormone peptide that igf-1 des is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. that small cut makes it bind poorly to the igf binding proteins that normally keep igf-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. it occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. there are no human trials of it at all, so everything said about it in people is extrapolation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or IGF-1 DES?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while IGF-1 DES is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and IGF-1 DES be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and IGF-1 DES together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.